Sabry, D., A. Mostafa, S. Marzouk, W. Ibrahim, H. H. M. Ali, A. Hassan, and A. Shamaa,
"Neupogen and mesenchymal stem cells are the novel therapeutic agents in regeneration of induced endometrial fibrosis in experimental rats.",
Bioscience reports, vol. 37, issue 5, 2017 Oct 31.
AbstractEndometrial fibrosis is the presence of intrauterine adhesions (IUAs) after any uterine surgery or curettage and it results in infertility and recurrent pregnancy loss. We evaluated the role of human mesenchymal stem cells (hMSCs) as a therapeutic agent of endometrial fibrosis. We also compared the effect of MSCs with the effect of estrogen and neupogen either each alone or as a combined therapy with MSCs. This experimental study was performed on 84 albino rats which were divided into seven groups (=12 rats/group) as follows, 1: normal control rats, 2: induced fibrosis, 3: induced fibrosis that received oral estrogen, 4: induced fibrosis that received hMSCs, 5: induced fibrosis that received hMSCs and estrogen, 6: induced fibrosis that received neupogen, and 7: induced fibrosis that received hMSCs and neupogen. The extent of fibrosis, vascularization, and inflammation were evaluated by; qRT-PCR for interleukin 1 (IL-1), interleukin 6 (IL-6), TNF, vascular endothelial growth factor (VEGF), transforming growth factor-β (TGF-β), and RUNX; ELISA for connective tissue growth factor (CTGF); Western blotting for collagen-I; immunohistochemistry examination for VEGF and RUNX-2; and histopathological assessment. In therapeutic groups either by hMSCs alone or combined with estrogen or neupogen; fibrosis and inflammation (IL-1, IL-6, TNF, TGF-β, RUNX, CTGF, and collagen-I) were significantly decreased but vascularization (VEGF) was significantly increased (<0.05) compared with induced fibrosis group. The most significant result was obtained in fibrosis that received combined therapy of hMSCs and neupogen (=0.000). Stem cells and neupogen are a highly effective alternative regenerative agents in endometrial fibrosis.
Sabry, D., A. Mostafa1, D. Mekawey, Z. Altaib, A. Shamaa, A. Hany, D. M, A. E. Hassib, N. E. Ibrahim, and W. A. Khalifa,
"An experimental model: intrauterine adhesion versus sub endometrial fibrosis",
Biomedical Research , vol. 29, issue 17, pp. 3311-3318, 2018.
Salem, N., M. Y. Salem, M. M. Elmaghrabi, M. A. Elawady, M. A. Elawady, D. Sabry, A. Shamaa, A. - H. H. Elkasapy, N. Ibrhim, and A. E. Amir,
"Does vitamin C have the ability to augment the therapeutic effect of bone marrow-derived mesenchymal stem cells on spinal cord injury?",
Neural Regeneration Research , vol. 12 (12), pp. 2050-2058, 2017.
Samer, M., F. A. Torad, A. A. Shamaa, O. S. El-Tookhy, D. S. A. Fatah, L. A. Rashed, M. A. Hamid, S. M. Mahfouz, and D. M. Gharib,
"Role of Endothelial Progenitor Cells in Management of Myocardial Infarction Following Total Coronary Occlusion in Dogs.",
Research Journal of Pharmaceutical, Biological and Chemical Sciences, vol. 7, issue 3, pp. 1225-1237, 2016.
Saravanan, S., N. Sareen1, E. Abu-El-Rub, H. Ashour, G. L. Sequiera, H. I. Ammar, V. Gopinath, A. A. Shamaa, S. S. E. Sayed, M. Moudgil, et al.,
"Graphene Oxide-Gold Nanosheets Containing Chitosan Scaffold Improves entricular Contractility and Function After Implantation into Infarcted Heart",
SCIENTIFIC RepOrtS , vol. 8, pp. 15069, 2018.
Shoukry, H. S., H. I. Ammar, L. A. Rashed, M. B. Zikri, A. A. Shamaa, S. G. Abou Elfadl, E. A. - A. Rub, S. Saravanan, and S. Dhingra,
"Prophylactic supplementation of resveratrol is more effective than its therapeutic use against doxorubicin induced cardiotoxicity.",
PloS one, vol. 12, issue 7, pp. e0181535, 2017.
AbstractResveratrol (RSV), a polyphenolic compound and naturally occurring phytoalexin, has been reported to exert cardio-protective effects in several animal studies. However, the outcome of initial clinical trials with RSV was less effective compared to pre-clinical studies. Therefore, RSV treatment protocols need to be optimized. In this study we evaluated prophylactic versus therapeutic effect of resveratrol (RSV) in mitigating doxorubicin (Dox)-induced cardiac toxicity in rats. To investigate prophylactic effects, RSV was supplemented for 2 weeks along with Dox administration. After 2 weeks, Dox treatment was stopped and RSV was continued for another 4 weeks. To study therapeutic effects, RSV treatment was initiated after 2 weeks of Dox administration and continued for 4 weeks. Both prophylactic and therapeutic use of RSV mitigated Dox induced deterioration of cardiac function as assessed by echocardiography. Also RSV treatment (prophylactic and therapeutic) prevented Dox induced myocardial damage as measured by cardiac enzymes (LDH and CK-MB) in serum. Which was associated with decrease in Dox induced myocardial apoptosis and fibrosis. Interestingly our study also reveals that prophylactic use of RSV was more effective than its therapeutic use in mitigating Dox induced apoptosis and fibrosis in the myocardium. Therefore, prophylactic use of resveratrol may be projected as a possible future adjuvant therapy to minimize cardiotoxic side effects of doxorubicin in cancer patients.
Soliman, A. S., M. S. Amer, A. A. Shamaa, D. Sabry, G. G. Shehab, and O. Hagag,
"Using of Chitosan seeded with autologous undifferentiated Mesenchymal Stem Cells for Femoral Bone Defect Management in dog",
Dogs. Research Journal of Pharmaceutical, Biological and Chemical Sciences (RJPBCS);, issue 6(4):1220-1231., 2015.